节点文献

特利加压素在肝硬化并发症临床应用的实践指导(2021版)

Practice Guidance on Use of Terlipressin for Liver Cirrhosis-related Complications(2021)

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 祁兴顺白朝辉谢渭芬朱强

【Author】 XIE Weifen;QI Xingshun;Hepatobiliary Study Group, Chinese Society of Gastroenterology, Chinese Medical Association;Hepatology Committee, Chinese Research Hospital Association;

【通讯作者】 祁兴顺;谢渭芬;

【机构】 中华医学会消化病学分会肝胆疾病学组中国研究型医院学会肝病专业委员会解放军北部战区总医院消化内科沈阳药科大学生命科学与生物制药学院解放军北部战区总医院消化内科海军军医大学第二附属医院(上海长征医院)消化内科山东第一医科大学附属省立医院消化内科

【摘要】 肝硬化患病人数多、死亡风险高,是全球疾病负担的重要组成部分之一。近年来,特利加压素在肝硬化相关并发症中的作用已逐渐得到认可。中华医学会消化病学分会肝胆疾病学组和中国研究型医院学会肝病专业委员会组织国内消化内科、肝病、感染性疾病、外科,以及临床药学领域的专家,在系统回顾当前循证医学证据的基础上,结合各位专家的临床经验,共制定了10条有关特利加压素在肝硬化并发症中临床应用的实践指导声明。特利加压素可使肝硬化伴急性食管胃静脉曲张出血或肝肾综合征患者获益,但在肝硬化伴腹水、穿刺后循环功能障碍、细菌感染,以及接受肝切除术或肝移植术患者中的应用证据仍不充分。此外,使用特利加压素时应密切监测不良事件的发生,主要包括胃肠道症状、电解质紊乱,以及心血管和呼吸系统不良事件。本部临床实践指导推荐特利加压素用于治疗肝硬化食管胃静脉曲张出血和肝肾综合征;但也指出,有待更多高质量的研究进一步探讨特利加压素对其他肝硬化相关并发症的疗效和安全性。

【Abstract】 Liver cirrhosis is a major global health burden worldwide due to its high risk of morbidity and mortality.Role of terlipressin for the management of liver cirrhosis-related complications has been recognized during recent years.This paper aims to develop evidence-based clinical practice guidance on the use of terlipressin for liver cirrhosis-related complications. Hepatobiliary Study Group of Chinese Society of Gastroenterology and Hepatology Committee of Chinese Research Hospital Association invited gastroenterologists, hepatologists, infectious disease specialists, surgeons, and clinical pharmacists to formulate the clinical practice guidance based on comprehensive literature review and experts’ clinical experiences. Overall, 10 major statements regarding efficacy and safety of terlipressin in liver cirrhosis-related complications were proposed. Terlipressin can be beneficial for the management of cirrhotic patients with acute gastroesophageal variceal bleeding and hepatorenal syndrome(HRS). However, the evidence regarding the use of terlipressin in cirrhotic patients with ascites, post-paracentesis circulatory dysfunction and bacterial infections, as well as in those undergoing hepatic resection and liver transplantation remains insufficient. Terlipressin-related adverse events,mainly including gastrointestinal symptoms, electrolyte disturbance, and cardiovascular and respiratory adverse events,should be closely monitored. The current clinical practice guidance supports the use of terlipressin for gastroesophageal variceal bleeding and HRS in liver cirrhosis. High-quality studies are needed to further clarify its potential effects in other liver cirrhosis-related complications.

  • 【文献出处】 胃肠病学 ,Chinese Journal of Gastroenterology , 编辑部邮箱 ,2022年09期
  • 【分类号】R575.2
  • 【下载频次】4
节点文献中: 

本文链接的文献网络图示:

本文的引文网络